Increased mobilization of mesenchymal stem cells in patients with acute respiratory distress syndrome undergoing extracorporeal membrane oxygenation.
Adult
Angiopoietin-2
/ blood
Case-Control Studies
Endothelial Progenitor Cells
/ cytology
Extracorporeal Membrane Oxygenation
Female
Humans
Leukocytes, Mononuclear
/ cytology
Male
Mesenchymal Stem Cells
/ cytology
Middle Aged
Respiratory Distress Syndrome
/ pathology
Vascular Endothelial Growth Factor A
/ blood
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
03
08
2019
accepted:
18
12
2019
entrez:
28
1
2020
pubmed:
28
1
2020
medline:
14
4
2020
Statut:
epublish
Résumé
The acute respiratory distress syndrome (ARDS) is characterized by pulmonary epithelial and endothelial barrier dysfunction and injury. In severe forms of ARDS, extracorporeal membrane oxygenation (ECMO) is often the last option for life support. Endothelial progenitor (EPC) and mesenchymal stem cells (MSC) can regenerate damaged endothelium and thereby improve pulmonary endothelial dysfunction. However, we still lack sufficient knowledge about how ECMO might affect EPC- and MSC-mediated regenerative pathways in ARDS. Therefore, we investigated if ECMO impacts EPC and MSC numbers in ARDS patients. Peripheral blood mononuclear cells from ARDS patients undergoing ECMO (n = 16) and without ECMO support (n = 12) and from healthy volunteers (n = 16) were isolated. The number and presence of circulating EPC and MSC was detected by flow cytometry. Serum concentrations of vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang2) were determined. In the ECMO group, MSC subpopulations were higher by 71% compared to the non-ECMO group. Numbers of circulating EPC were not significantly altered. During ECMO, VEGF and Ang2 serum levels remained unchanged compared to the non-ECMO group (p = 0.16), but Ang2 serum levels in non-survivors of ARDS were significantly increased by 100% (p = 0.02) compared to survivors. ECMO support in ARDS is specifically associated with an increased number of circulating MSC, most likely due to enhanced mobilization, but not with a higher numbers of EPC or serum concentrations of VEGF and Ang2.
Sections du résumé
BACKGROUND
The acute respiratory distress syndrome (ARDS) is characterized by pulmonary epithelial and endothelial barrier dysfunction and injury. In severe forms of ARDS, extracorporeal membrane oxygenation (ECMO) is often the last option for life support. Endothelial progenitor (EPC) and mesenchymal stem cells (MSC) can regenerate damaged endothelium and thereby improve pulmonary endothelial dysfunction. However, we still lack sufficient knowledge about how ECMO might affect EPC- and MSC-mediated regenerative pathways in ARDS. Therefore, we investigated if ECMO impacts EPC and MSC numbers in ARDS patients.
METHODS
Peripheral blood mononuclear cells from ARDS patients undergoing ECMO (n = 16) and without ECMO support (n = 12) and from healthy volunteers (n = 16) were isolated. The number and presence of circulating EPC and MSC was detected by flow cytometry. Serum concentrations of vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang2) were determined.
RESULTS
In the ECMO group, MSC subpopulations were higher by 71% compared to the non-ECMO group. Numbers of circulating EPC were not significantly altered. During ECMO, VEGF and Ang2 serum levels remained unchanged compared to the non-ECMO group (p = 0.16), but Ang2 serum levels in non-survivors of ARDS were significantly increased by 100% (p = 0.02) compared to survivors.
CONCLUSIONS
ECMO support in ARDS is specifically associated with an increased number of circulating MSC, most likely due to enhanced mobilization, but not with a higher numbers of EPC or serum concentrations of VEGF and Ang2.
Identifiants
pubmed: 31986159
doi: 10.1371/journal.pone.0227460
pii: PONE-D-19-21924
pmc: PMC6984734
doi:
Substances chimiques
Angiopoietin-2
0
Vascular Endothelial Growth Factor A
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0227460Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Clin Invest. 2012 Jun;122(6):1991-2005
pubmed: 22585576
N Engl J Med. 2000 May 4;342(18):1301-8
pubmed: 10793162
J Histochem Cytochem. 2014 Feb;62(2):103-8
pubmed: 24309509
Am J Respir Crit Care Med. 2010 Feb 1;181(3):226-37
pubmed: 19875689
Biochem Biophys Res Commun. 2008 Nov 14;376(2):419-22
pubmed: 18789891
Mol Med Rep. 2016 Oct;14(4):3862-70
pubmed: 27600821
Crit Care Med. 1994 Sep;22(9):1406-11
pubmed: 8062562
J Mol Cell Cardiol. 2008 Oct;45(4):530-44
pubmed: 18755197
Biochem Biophys Res Commun. 2005 Oct 21;336(2):392-6
pubmed: 16129411
Am J Physiol Renal Physiol. 2018 Oct 1;315(4):F861-F869
pubmed: 29513070
Crit Care. 2019 Feb 13;23(1):44
pubmed: 30760290
Artif Organs. 2016 Jun;40(6):577-85
pubmed: 26510997
Thorax. 2006 Jul;61(7):621-6
pubmed: 16807391
J Inflamm (Lond). 2018 May 16;15:10
pubmed: 29796010
Am J Respir Cell Mol Biol. 2013 Apr;48(4):399-405
pubmed: 23103996
Nat Protoc. 2007;2(4):805-10
pubmed: 17446880
Bone. 2012 Apr;50(4):1012-8
pubmed: 22342795
Stem Cells. 2004;22(3):377-84
pubmed: 15153614
Thorax. 2019 Feb;74(2):194-196
pubmed: 29622695
BMC Med Genomics. 2010 May 13;3:18
pubmed: 20465783
Intensive Care Med. 2015 Nov;41(11):1986-9
pubmed: 26224249
Am J Respir Cell Mol Biol. 2010 Sep;43(3):326-33
pubmed: 19843706
Shock. 2005 Jan;23(1):35-8
pubmed: 15614129
Crit Care Med. 2007 Jul;35(7):1677-84
pubmed: 17522579
Front Immunol. 2013 Mar 04;4:49
pubmed: 23459632
Dis Markers. 2017;2017:6758721
pubmed: 28947844
Anesth Analg. 2008 Jun;106(6):1820-6
pubmed: 18499616
Nat Med. 2002 Mar;8(3):194-5
pubmed: 11875467
Lancet Respir Med. 2015 Jan;3(1):24-32
pubmed: 25529339
Am J Respir Crit Care Med. 2005 Oct 1;172(7):854-60
pubmed: 15976374
Cytotherapy. 2006;8(4):315-7
pubmed: 16923606
Stem Cells Int. 2017;2017:5173732
pubmed: 28286525
Proc Natl Acad Sci U S A. 2007 Jun 26;104(26):11002-7
pubmed: 17569781
JAMA. 2012 Jun 20;307(23):2526-33
pubmed: 22797452
J Cell Mol Med. 2010 Oct;14(10):2436-47
pubmed: 19968735
Circ Res. 2003 Aug 22;93(4):372-9
pubmed: 12881479
Mediators Inflamm. 2018 Jun 12;2018:1739615
pubmed: 30008611
J Perinatol. 2010 Nov;30(11):724-30
pubmed: 20336079
J Thorac Dis. 2015 Jul;7(7):E166-76
pubmed: 26380745
Shock. 2008 Jun;29(6):656-61
pubmed: 18091573
J Rheumatol. 2011 Feb;38(2):339-49
pubmed: 21078714
PLoS One. 2018 Mar 30;13(3):e0195064
pubmed: 29601599
ASAIO J. 2019 Jun 5;:null
pubmed: 31192851
JAMA. 1993 Dec 22-29;270(24):2957-63
pubmed: 8254858
J Exp Med. 2001 May 7;193(9):1005-14
pubmed: 11342585